AstraZeneca: Rhinitis, Allergic trials

The registry lists 12 Rhinitis, Allergic studies with AstraZeneca as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 3Phase 3 5Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mLCompletedNCT01544348Phase 1Results posted
• Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848CompletedNCT01185080Phase 2Results posted
• Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848CompletedNCT00770003Phase 1
• Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of SeasonCompletedNCT00688779Phase 1
• New Nasal Applicator / New Formulation - User StudyCompletedNCT00641979Phase 2
• Assess the Efficacy and Safety of Rhinocort AquaCompletedNCT00641693Phase 2
• Children, Perennial Allergic Rhinitis (PAR), l-t GrowthCompletedNCT00641212Phase 4
• Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)CompletedNCT00305487Phase 3
• Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)CompletedNCT00261287Phase 3
• Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)CompletedNCT00163514Phase 3
• Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)CompletedNCT00163501Phase 3
• Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)CompletedNCT00163488Phase 3